Stock & Company Details
Iovance Biotherapeutics Inc $IOVA
Price:
N/A
N/A
453M
$3.7B
52 Week High:
N/A
10 Day Average Volume:
N/A
-11.11
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
IOVA technical indicators
Latest Iovance Biotherapeutics Inc (IOVA) indicator readings as of 2026-08-28.
IOVA's 14-day RSI is 63.8, in neutral territory. At $8.01 it is trading 112.0% above its 200-day moving average of $3.78, and above its 50-day average of $5.46. Price sits in the middle of its Bollinger Bands ($4.24 to $9.66). ADX reads 51.0, indicating a trending market.
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Finance Bot
Ask your questions
Start by typing a question below.
